Literature DB >> 9851585

Tyrosine kinase inhibitors suppress prostaglandin F2alpha-induced phosphoinositide hydrolysis, Ca2+ elevation and contraction in iris sphincter smooth muscle.

S Y Yousufzai1, A A Abdel-Latif.   

Abstract

We investigated the effects of the protein tyrosine kinase inhibitors, genistein, tyrphostin 47, and herbimycin on prostaglandin F2alpha- and carbachol-induced inositol-1,4,5-trisphosphate (IP3) production, [Ca2+]i mobilization and contraction in cat iris sphincter smooth muscle. Prostaglandin F2alpha and carbachol induced contraction in a concentration-dependent manner with EC50 values of 0.92 x 10(-9) and 1.75 x 10(-8) M, respectively. The protein tyrosine kinase inhibitors blocked the stimulatory effects of prostaglandin F2alpha, but not those evoked by carbachol, on IP3 accumulation, [Ca2+]i mobilization and contraction, suggesting involvement of protein tyrosine kinase activity in the physiological actions of the prostaglandin. Daidzein and tyrphostin A, inactive negative control compounds for genistein and tyrphostin 47, respectively, were without effect. Latanoprost, a prostaglandin F2alpha analog used as an antiglaucoma drug, induced contraction and this effect was blocked by genistein. Genistein (10 microM) markedly reduced (by 67%) prostaglandin F2alpha-stimulated increase in [Ca2+]i but had little effect on that of carbachol in cat iris sphincter smooth muscle cells. Vanadate, a potent inhibitor of protein tyrosine phosphatase, induced a slow gradual muscle contraction in a concentration-dependent manner with an EC50 of 82 microM and increased IP3 generation in a concentration-dependent manner with an EC50 of 90 microM. The effects of vanadate were abolished by genistein (10 microM). Wortmannin, a myosin light chain kinase inhibitor, reduced prostaglandin F2alpha- and carbachol-induced contraction, suggesting that the involvement of protein tyrosine kinase activity may lie upstream of the increases in [Ca2+]i evoked by prostaglandin F2alpha. Further studies aimed at elucidating the role of protein tyrosine kinase activity in the coupling mechanism between prostaglandin F2alpha receptor activation and increases in intracellular Ca2+ mobilization and identifying the tyrosine-phosphorylated substrates will provide important information about the role of protein tyrosine kinase in the mechanism of smooth muscle contraction, as well as about the mechanism of the intraocular pressure lowering effect of the prostaglandin in glaucoma patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851585     DOI: 10.1016/s0014-2999(98)00697-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation.

Authors:  X Chen; H Zhou; Y B Liu; J F Wang; H Li; C Y Ung; L Y Han; Z W Cao; Y Z Chen
Journal:  Br J Pharmacol       Date:  2006-11-06       Impact factor: 8.739

2.  Phospholipid profiles of control and glaucomatous human aqueous humor.

Authors:  Genea Edwards; Katyayini Aribindi; Yenifer Guerra; Richard K Lee; Sanjoy K Bhattacharya
Journal:  Biochimie       Date:  2014-02-21       Impact factor: 4.079

3.  Transcription profiling in Drosophila eyes that overexpress the human glaucoma-associated trabecular meshwork-inducible glucocorticoid response protein/myocilin (TIGR/MYOC).

Authors:  Teresa Borrás; Tatiana V Morozova; Stefanie L Heinsohn; Richard F Lyman; Trudy F C Mackay; Robert R H Anholt
Journal:  Genetics       Date:  2003-02       Impact factor: 4.562

4.  Comparative phospholipid profiles of control and glaucomatous human trabecular meshwork.

Authors:  Katyayini Aribindi; Yenifer Guerra; Richard K Lee; Sanjoy K Bhattacharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-30       Impact factor: 4.799

5.  Prostaglandin F2(alpha) stimulates growth of skeletal muscle cells via an NFATC2-dependent pathway.

Authors:  Valerie Horsley; Grace K Pavlath
Journal:  J Cell Biol       Date:  2003-04-14       Impact factor: 10.539

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.